Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Harvard Business School
Mallinckrodt
Express Scripts

Last Updated: September 25, 2022

TROKENDI XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Trokendi Xr patents expire, and what generic alternatives are available?

Trokendi Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in eight countries.

The generic ingredient in TROKENDI XR is topiramate. There are twenty-six drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the topiramate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Trokendi Xr

A generic version of TROKENDI XR was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.

  Try it Free

Drug patent expirations by year for TROKENDI XR
Drug Prices for TROKENDI XR

See drug prices for TROKENDI XR

Drug Sales Revenue Trends for TROKENDI XR

See drug sales revenues for TROKENDI XR

Recent Clinical Trials for TROKENDI XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Supernus Pharmaceuticals, Inc.Phase 2
University of Minnesota - Clinical and Translational Science InstitutePhase 2
University of MinnesotaPhase 2

See all TROKENDI XR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TROKENDI XR
Paragraph IV (Patent) Challenges for TROKENDI XR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TROKENDI XR Extended-release Capsules topiramate 25 mg, 50 mg, and 100 mg 201635 1 2014-05-12
TROKENDI XR Extended-release Capsules topiramate 200 mg 201635 1 2014-04-03

US Patents and Regulatory Information for TROKENDI XR

TROKENDI XR is protected by twenty US patents.

Patents protecting TROKENDI XR

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE

Sustained-release formulations of topiramate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 BC RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB1 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB1 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB1 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 BC RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB1 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB1 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TROKENDI XR

See the table below for patents covering TROKENDI XR around the world.

Country Patent Number Title Estimated Expiration
Spain 2555066 See Plans and Pricing
Japan 5489719 See Plans and Pricing
Mexico 2009001711 FORMULACIONES DE LIBERACION SOSTENIDA DE TOPIRAMATO. (SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE.) See Plans and Pricing
Japan 2010510241 See Plans and Pricing
Spain 2312308 See Plans and Pricing
European Patent Office 1973528 FORMULATIONS DE TOPIRAMATE À LIBÉRATION PROLONGÉE (SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE) See Plans and Pricing
Germany 07870164 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TROKENDI XR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138441 SPC/GB95/028 United Kingdom See Plans and Pricing PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Boehringer Ingelheim
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.